Multiple Sclerosis: The Hidden Truth About Its Two Strikingly Different Forms

One diagnosis, two trajectories

Multiple sclerosis is both an autoimmune and neurodegenerative condition. The immune system attacks the myelin sheath that insulates neurons, disrupting nerve signals and setting off a cascade of damage. Over time, axons and neurons can be lost, driving lasting disability.

Clinicians have long observed that MS is deeply heterogeneous, even under the same label. Some people face frequent inflammatory relapses, while others experience a quieter but steadier decline. New research suggests these differences reflect two distinct trajectories, hidden behind one diagnosis.

What recent evidence reveals

By pairing advanced brain MRI with a blood marker called serum neurofilament light chain (sNfL), researchers mapped how damage accumulates. Using an AI model, they identified two patterns that best explain clinical and biological data. One is inflammation‑first, the other neurodegeneration‑first, each with a different tempo.

In the inflammation‑first path, inflammatory activity is prominent early, with sNfL rising alongside active lesions. In the neurodegeneration‑first path, brain volume declines before blood biomarkers markedly increase. Taken together, these patterns formalize what many neurologists suspected, but could not cleanly define.

“As one neurologist put it, this two‑trajectory framework helps us ‘anticipate the future, at least in a directional way.’”

How the two forms tend to differ

These trajectories are not hard categories, and individuals can shift. Still, they offer practical clues for earlier stratification and tailored care. The contrasts often appear in symptoms, imaging, and timelines.

• Inflammation‑first: frequent early relapses, new MRI lesions with gadolinium enhancement.
• Inflammation‑first: rapid sNfL spikes tracking inflammatory bursts.
• Neurodegeneration‑first: gradual functional decline without clear early relapses.
• Neurodegeneration‑first: early global or regional brain atrophy, with subtler lesions.
• Both forms: accumulated disability that reflects total tissue loss, not just relapses.

Why the split matters for treatment

Most current MS therapies are strongly anti‑inflammatory, and they cut relapse risk significantly. They are less effective at halting slow axonal loss or restoring damaged myelin. Recognizing the trajectory earlier could sharpen when and how we deploy specific strategies, beyond a one‑size‑fits‑all playbook.

For an inflammation‑first course, rapid escalation to high‑efficacy therapy may prevent early damage. For a neurodegeneration‑first course, we may need earlier emphasis on neuroprotective targets and remyelination‑focused trials. Stratified trial design could speed discovery of treatments that match each trajectory, rather than dilute effects across mixed populations.

Patients also gain clearer counseling, since the near‑term risks and long‑term goals differ. An inflammation‑first path may prioritize blocking relapses, while the other emphasizes slowing silent tissue loss. Either way, the aim is earlier, smarter, and more durable protection of the central nervous system.

Caution: prediction is not destiny

These findings are promising, but they are not a crystal ball. sNfL is not yet a routine test everywhere, and individual‑level prediction still needs careful validation. Biology is noisy, and comorbidities or life events can shift a person’s MS course.

MRI protocols vary, and volumetric metrics demand standardized acquisition and rigorous analysis. sNfL reflects global injury, not its exact source, and values can fluctuate with infections or other stressors. True precision will likely blend imaging, fluid biomarkers, clinical features, and longitudinal patterns.

What clinicians and patients can do now

Even before universal biomarker access, this framework encourages practical, evidence‑based steps. The goal is to capture both inflammatory bursts and the slow burn of structural loss.

• Track relapse activity and MRI lesion load with consistent protocols.
• Add quantitative MRI when possible to monitor brain atrophy over time.
• Use sNfL judiciously where available to flag active injury, not just inflammation.
• Escalate therapy promptly in clear inflammation‑first courses, minimizing early damage.
• Consider enrollment in neuroprotection and remyelination trials for progressive features.
• Pair disease‑modifying therapy with lifestyle supports like exercise and sleep hygiene.

The road to personalized MS care

The two‑trajectory model reframes MS as a shared label with diverging roads. It pushes research toward targeted endpoints, and care toward earlier, tailored decisions. Big‑cohort data, richer imaging, and multimodal biomarkers can turn pattern detection into patient‑level precision.

Ultimately, better stratification can save neurons, preserve function, and help people stay ahead of a complex, shape‑shifting disease. By recognizing MS as both inflammatory and degenerative, we open space for therapies that counter each force. One disease, yes—but with two distinct forms, calling for two smart, coordinated responses.